Angiotensin-converting enzyme inhibitors and coronary artery disease
The renin-angiotensin system and angiotensin converting enzyme (ACE) are increasingly being implicated in the pathogenesis of coronary artery disease and its sequelae. Genetic studies of ACE gene polymorphism hint at an association between the ACE genotype and atherosclerosis. Animal studies have de...
Gespeichert in:
| Veröffentlicht in: | Cardiovascular drugs and therapy 1996-11, Vol.10 (S2), p.631-637 |
|---|---|
| Hauptverfasser: | , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 637 |
|---|---|
| container_issue | S2 |
| container_start_page | 631 |
| container_title | Cardiovascular drugs and therapy |
| container_volume | 10 |
| creator | SAYER, J. W TIMMIS, A. D |
| description | The renin-angiotensin system and angiotensin converting enzyme (ACE) are increasingly being implicated in the pathogenesis of coronary artery disease and its sequelae. Genetic studies of ACE gene polymorphism hint at an association between the ACE genotype and atherosclerosis. Animal studies have demonstrated the potential beneficial effects of ACE inhibition at a variety of sites, including improvement of endothelial function, inhibition of platelet aggregation, reduction of atherosclerosis, and inhibition of myointimal proliferation. Although these have not all been validated in human studies, the reduction of ischemic events in studies of ACE inhibition in left ventricular dysfunction cannot be explained solely by improved hemodynamics, and it is possible that actions on the endothelium, the atherosclerotic process, and platelets are at least in part responsible. The results of studies in humans looking more directly at the influence of ACE inhibitors on atherosclerosis and ischemic heart disease are awaited. |
| doi_str_mv | 10.1007/BF00052510 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_78681350</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>78681350</sourcerecordid><originalsourceid>FETCH-LOGICAL-c311t-2cc65bcf1d2e9143f720cb38f36bd1e7b17d08c4cbc508b11ac02c8813d41b893</originalsourceid><addsrcrecordid>eNpFkMFLwzAchYMoc04v3oUexINQzS9pmuQ4p1Nh4EXPJUnTGWnTmXTC_OuNWObpHd7H4_EhdA74BjDmt3dLjDEjDPABmgLjNOekgEM0xZLgnBJcHqOTGD8SxaUUEzSRAEwyPkX3c792_WB9dD43vf-yYXB-nVn_vets5vy7027oQ8yUrzPTh96rsMtUGGyK2kWroj1FR41qoz0bc4belg-vi6d89fL4vJivckMBhpwYUzJtGqiJlVDQhhNsNBUNLXUNlmvgNRamMNowLDSAMpgYIYDWBWgh6Qxd_e1uQv-5tXGoOheNbVvlbb-NFRdlghlO4PUfaEIfY7BNtQmuS8crwNWvsupfWYIvxtWt7my9R0dHqb8cexWNapugvHFxjxGWnEpGfwCPR3Ms</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>78681350</pqid></control><display><type>article</type><title>Angiotensin-converting enzyme inhibitors and coronary artery disease</title><source>MEDLINE</source><source>SpringerLink Journals - AutoHoldings</source><creator>SAYER, J. W ; TIMMIS, A. D</creator><creatorcontrib>SAYER, J. W ; TIMMIS, A. D</creatorcontrib><description>The renin-angiotensin system and angiotensin converting enzyme (ACE) are increasingly being implicated in the pathogenesis of coronary artery disease and its sequelae. Genetic studies of ACE gene polymorphism hint at an association between the ACE genotype and atherosclerosis. Animal studies have demonstrated the potential beneficial effects of ACE inhibition at a variety of sites, including improvement of endothelial function, inhibition of platelet aggregation, reduction of atherosclerosis, and inhibition of myointimal proliferation. Although these have not all been validated in human studies, the reduction of ischemic events in studies of ACE inhibition in left ventricular dysfunction cannot be explained solely by improved hemodynamics, and it is possible that actions on the endothelium, the atherosclerotic process, and platelets are at least in part responsible. The results of studies in humans looking more directly at the influence of ACE inhibitors on atherosclerosis and ischemic heart disease are awaited.</description><identifier>ISSN: 0920-3206</identifier><identifier>EISSN: 1573-7241</identifier><identifier>DOI: 10.1007/BF00052510</identifier><identifier>PMID: 9115957</identifier><identifier>CODEN: CDTHET</identifier><language>eng</language><publisher>Dordrecht: Springer</publisher><subject>Angiotensin-Converting Enzyme Inhibitors - administration & dosage ; Angiotensin-Converting Enzyme Inhibitors - pharmacology ; Angiotensin-Converting Enzyme Inhibitors - therapeutic use ; Animals ; Arteriosclerosis - drug therapy ; Biological and medical sciences ; Cardiology. Vascular system ; Cardiomegaly - etiology ; Cardiomegaly - prevention & control ; Clinical Trials as Topic ; Coronary Disease - drug therapy ; Coronary Disease - etiology ; Coronary Disease - prevention & control ; Coronary heart disease ; Endothelium, Vascular - drug effects ; Gene Expression Regulation, Enzymologic - drug effects ; Gene Expression Regulation, Enzymologic - genetics ; Heart ; Hemodynamics - drug effects ; Hemostasis - drug effects ; Humans ; Medical sciences ; Myocardial Ischemia - drug therapy ; Myocarditis. Cardiomyopathies ; Peptidyl-Dipeptidase A - genetics ; Polymorphism, Genetic - genetics ; Renin-Angiotensin System - drug effects ; Ventricular Function, Left - drug effects</subject><ispartof>Cardiovascular drugs and therapy, 1996-11, Vol.10 (S2), p.631-637</ispartof><rights>1997 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c311t-2cc65bcf1d2e9143f720cb38f36bd1e7b17d08c4cbc508b11ac02c8813d41b893</citedby><cites>FETCH-LOGICAL-c311t-2cc65bcf1d2e9143f720cb38f36bd1e7b17d08c4cbc508b11ac02c8813d41b893</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>309,310,314,776,780,785,786,23909,23910,25118,27901,27902</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=2579995$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/9115957$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>SAYER, J. W</creatorcontrib><creatorcontrib>TIMMIS, A. D</creatorcontrib><title>Angiotensin-converting enzyme inhibitors and coronary artery disease</title><title>Cardiovascular drugs and therapy</title><addtitle>Cardiovasc Drugs Ther</addtitle><description>The renin-angiotensin system and angiotensin converting enzyme (ACE) are increasingly being implicated in the pathogenesis of coronary artery disease and its sequelae. Genetic studies of ACE gene polymorphism hint at an association between the ACE genotype and atherosclerosis. Animal studies have demonstrated the potential beneficial effects of ACE inhibition at a variety of sites, including improvement of endothelial function, inhibition of platelet aggregation, reduction of atherosclerosis, and inhibition of myointimal proliferation. Although these have not all been validated in human studies, the reduction of ischemic events in studies of ACE inhibition in left ventricular dysfunction cannot be explained solely by improved hemodynamics, and it is possible that actions on the endothelium, the atherosclerotic process, and platelets are at least in part responsible. The results of studies in humans looking more directly at the influence of ACE inhibitors on atherosclerosis and ischemic heart disease are awaited.</description><subject>Angiotensin-Converting Enzyme Inhibitors - administration & dosage</subject><subject>Angiotensin-Converting Enzyme Inhibitors - pharmacology</subject><subject>Angiotensin-Converting Enzyme Inhibitors - therapeutic use</subject><subject>Animals</subject><subject>Arteriosclerosis - drug therapy</subject><subject>Biological and medical sciences</subject><subject>Cardiology. Vascular system</subject><subject>Cardiomegaly - etiology</subject><subject>Cardiomegaly - prevention & control</subject><subject>Clinical Trials as Topic</subject><subject>Coronary Disease - drug therapy</subject><subject>Coronary Disease - etiology</subject><subject>Coronary Disease - prevention & control</subject><subject>Coronary heart disease</subject><subject>Endothelium, Vascular - drug effects</subject><subject>Gene Expression Regulation, Enzymologic - drug effects</subject><subject>Gene Expression Regulation, Enzymologic - genetics</subject><subject>Heart</subject><subject>Hemodynamics - drug effects</subject><subject>Hemostasis - drug effects</subject><subject>Humans</subject><subject>Medical sciences</subject><subject>Myocardial Ischemia - drug therapy</subject><subject>Myocarditis. Cardiomyopathies</subject><subject>Peptidyl-Dipeptidase A - genetics</subject><subject>Polymorphism, Genetic - genetics</subject><subject>Renin-Angiotensin System - drug effects</subject><subject>Ventricular Function, Left - drug effects</subject><issn>0920-3206</issn><issn>1573-7241</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1996</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpFkMFLwzAchYMoc04v3oUexINQzS9pmuQ4p1Nh4EXPJUnTGWnTmXTC_OuNWObpHd7H4_EhdA74BjDmt3dLjDEjDPABmgLjNOekgEM0xZLgnBJcHqOTGD8SxaUUEzSRAEwyPkX3c792_WB9dD43vf-yYXB-nVn_vets5vy7027oQ8yUrzPTh96rsMtUGGyK2kWroj1FR41qoz0bc4belg-vi6d89fL4vJivckMBhpwYUzJtGqiJlVDQhhNsNBUNLXUNlmvgNRamMNowLDSAMpgYIYDWBWgh6Qxd_e1uQv-5tXGoOheNbVvlbb-NFRdlghlO4PUfaEIfY7BNtQmuS8crwNWvsupfWYIvxtWt7my9R0dHqb8cexWNapugvHFxjxGWnEpGfwCPR3Ms</recordid><startdate>19961101</startdate><enddate>19961101</enddate><creator>SAYER, J. W</creator><creator>TIMMIS, A. D</creator><general>Springer</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>19961101</creationdate><title>Angiotensin-converting enzyme inhibitors and coronary artery disease</title><author>SAYER, J. W ; TIMMIS, A. D</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c311t-2cc65bcf1d2e9143f720cb38f36bd1e7b17d08c4cbc508b11ac02c8813d41b893</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1996</creationdate><topic>Angiotensin-Converting Enzyme Inhibitors - administration & dosage</topic><topic>Angiotensin-Converting Enzyme Inhibitors - pharmacology</topic><topic>Angiotensin-Converting Enzyme Inhibitors - therapeutic use</topic><topic>Animals</topic><topic>Arteriosclerosis - drug therapy</topic><topic>Biological and medical sciences</topic><topic>Cardiology. Vascular system</topic><topic>Cardiomegaly - etiology</topic><topic>Cardiomegaly - prevention & control</topic><topic>Clinical Trials as Topic</topic><topic>Coronary Disease - drug therapy</topic><topic>Coronary Disease - etiology</topic><topic>Coronary Disease - prevention & control</topic><topic>Coronary heart disease</topic><topic>Endothelium, Vascular - drug effects</topic><topic>Gene Expression Regulation, Enzymologic - drug effects</topic><topic>Gene Expression Regulation, Enzymologic - genetics</topic><topic>Heart</topic><topic>Hemodynamics - drug effects</topic><topic>Hemostasis - drug effects</topic><topic>Humans</topic><topic>Medical sciences</topic><topic>Myocardial Ischemia - drug therapy</topic><topic>Myocarditis. Cardiomyopathies</topic><topic>Peptidyl-Dipeptidase A - genetics</topic><topic>Polymorphism, Genetic - genetics</topic><topic>Renin-Angiotensin System - drug effects</topic><topic>Ventricular Function, Left - drug effects</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>SAYER, J. W</creatorcontrib><creatorcontrib>TIMMIS, A. D</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Cardiovascular drugs and therapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>SAYER, J. W</au><au>TIMMIS, A. D</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Angiotensin-converting enzyme inhibitors and coronary artery disease</atitle><jtitle>Cardiovascular drugs and therapy</jtitle><addtitle>Cardiovasc Drugs Ther</addtitle><date>1996-11-01</date><risdate>1996</risdate><volume>10</volume><issue>S2</issue><spage>631</spage><epage>637</epage><pages>631-637</pages><issn>0920-3206</issn><eissn>1573-7241</eissn><coden>CDTHET</coden><abstract>The renin-angiotensin system and angiotensin converting enzyme (ACE) are increasingly being implicated in the pathogenesis of coronary artery disease and its sequelae. Genetic studies of ACE gene polymorphism hint at an association between the ACE genotype and atherosclerosis. Animal studies have demonstrated the potential beneficial effects of ACE inhibition at a variety of sites, including improvement of endothelial function, inhibition of platelet aggregation, reduction of atherosclerosis, and inhibition of myointimal proliferation. Although these have not all been validated in human studies, the reduction of ischemic events in studies of ACE inhibition in left ventricular dysfunction cannot be explained solely by improved hemodynamics, and it is possible that actions on the endothelium, the atherosclerotic process, and platelets are at least in part responsible. The results of studies in humans looking more directly at the influence of ACE inhibitors on atherosclerosis and ischemic heart disease are awaited.</abstract><cop>Dordrecht</cop><pub>Springer</pub><pmid>9115957</pmid><doi>10.1007/BF00052510</doi><tpages>7</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0920-3206 |
| ispartof | Cardiovascular drugs and therapy, 1996-11, Vol.10 (S2), p.631-637 |
| issn | 0920-3206 1573-7241 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_78681350 |
| source | MEDLINE; SpringerLink Journals - AutoHoldings |
| subjects | Angiotensin-Converting Enzyme Inhibitors - administration & dosage Angiotensin-Converting Enzyme Inhibitors - pharmacology Angiotensin-Converting Enzyme Inhibitors - therapeutic use Animals Arteriosclerosis - drug therapy Biological and medical sciences Cardiology. Vascular system Cardiomegaly - etiology Cardiomegaly - prevention & control Clinical Trials as Topic Coronary Disease - drug therapy Coronary Disease - etiology Coronary Disease - prevention & control Coronary heart disease Endothelium, Vascular - drug effects Gene Expression Regulation, Enzymologic - drug effects Gene Expression Regulation, Enzymologic - genetics Heart Hemodynamics - drug effects Hemostasis - drug effects Humans Medical sciences Myocardial Ischemia - drug therapy Myocarditis. Cardiomyopathies Peptidyl-Dipeptidase A - genetics Polymorphism, Genetic - genetics Renin-Angiotensin System - drug effects Ventricular Function, Left - drug effects |
| title | Angiotensin-converting enzyme inhibitors and coronary artery disease |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-28T23%3A13%3A26IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Angiotensin-converting%20enzyme%20inhibitors%20and%20coronary%20artery%20disease&rft.jtitle=Cardiovascular%20drugs%20and%20therapy&rft.au=SAYER,%20J.%20W&rft.date=1996-11-01&rft.volume=10&rft.issue=S2&rft.spage=631&rft.epage=637&rft.pages=631-637&rft.issn=0920-3206&rft.eissn=1573-7241&rft.coden=CDTHET&rft_id=info:doi/10.1007/BF00052510&rft_dat=%3Cproquest_cross%3E78681350%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=78681350&rft_id=info:pmid/9115957&rfr_iscdi=true |